Summary:
IMI consultation workshop on Oncology

Stefan J. Scherer
29.09.2016 • IMI Stakeholder Forum 2016 • Brussels, Belgium
Objectives of the SGG Oncology - Integrated Dynamic Personalized Cancer Care - IDPCC

Beyond patient stratification
- gathering large amounts of longitudinal diagnostic and treatment information
- how the function of these networks are altered by treatment, and how cells adapt to pharmacological treatment, including resistance mechanisms vs. escape for checkpoint.

Context specificity - MutOomics
- No two tumours behave the same, even after stratifying samples based on genotype and pre-selecting those that could reasonably be presumed similar
- systematically explore and predict contextual dependencies will require complex studies to test different drugs in different context and different indications

Immune Oncology – Tumor microenvironment
- Further advances can be fostered via a multi-pronged approach to continue to develop next generation IO and targeted monotherapies to augment our current treatment arsenal, and define IO
- Targeted or even IO – IO treatment combinations or sequencing of therapy that may show broad efficacy in previously challenging to treat tumour conditions

Cell Free DNA – Liquid Biopsy
- cfDNA assessment could also allow to overcome the challenges of tumour heterogeneity both spatial and temporal as well as triggered by treatment pressure.

The Era of Big Data – HARMONY, THE BIG 5, Prostate Initiative
Highlights of this consultation workshop

- Access to innovative medicine
- Comparator / placebo arm still needed – waste of patients
- Endpoints: PRO? Imaging? Molecular endpoints?
- Moving away from controlled trials – no 2 pts are alike
- Outcomes for pts – Precision medicine as a tool for better outcomes
- Platforms: Achievable, Affordable, Acceptable
Projects

**HARMONY**
- Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies

**MutOmics**
- Identify the interdependencies of tumor mutations, stromal factor, extracellular matrix and gene expressions in order to identify responder populations differently.

**The “Big 5”, Prostate Cancer Initiative**
- RWE (Real world evidence) is a key factor to improve cancer outcome and establish meaningful endpoints, treatment sequences and toxicities.

**Tumor microenvironment**
- Profiling specifically designed to deeply interrogate tumor microenvironment and patient immune system over time
Gap Check

What do we need to focus on to complete our strategy, reach our goal and demonstrate the impact on cancer patient and society?

IDPCC is the cornerstone of success, more is needed to take it from research to patient and transform it to “Real Time Oncology”
The Silos are for Farms, not for Pharma

Fostering Collaboration and Exchange

Source: http://www.whatcounts.com/2012/08/marketing-silos-will-kill-your-business/